Overview

Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

Status:
Active, not recruiting

Trial end date:
2021-12-30

Target enrollment:

Participant gender:

Summary

"•Prospective, open label, randomized, multicenter study - Patients treated with a new generation of Everolimus-eluting stents (Synergy®). After PTCA, patients are randomized to a group of DAPT for one year or a group of P2Y12 monotherapy after 3 months of DAPT. After 12 months of PTCA, evaluate major cardiovascular events and major bleeding events - This study is to confirm after PTCA, DAPT for three months is not considered to be inferior to keeping DAPT for a year.

Phase:

N/A

Details

Lead Sponsor:

Gangnam Severance Hospital

Treatments:

Aspirin
Clopidogrel
Everolimus
Ticagrelor